169
Participants
Start Date
July 13, 2018
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
ABBV-155
Intravenous (IV) Infusion
Paclitaxel
Intravenous (IV) Infusion
Docetaxel
Intravenous (IV) Infusion
National Taiwan University Hospital /ID# 205673, Taipei City
National Cheng Kung University Hospital /ID# 206304, Tainan City
Peter MacCallum Cancer Center /ID# 241676, Melbourne
National Cancer Center /ID# 241095, Goyang-si
Johns Hopkins Bayview Med Cnt /ID# 215095, Baltimore
Johns Hopkins Hospital /ID# 201320, Baltimore
Hospital Universitario Fundacion Jimenez Diaz /ID# 239997, Madrid
Hospital Universitario 12 de Octubre /ID# 239999, Madrid
Carolina BioOncology Institute /ID# 201577, Huntersville
AdventHealth Orlando /ID# 227242, Orlando
University of Alabama at Birmingham - Main /ID# 214024, Birmingham
China Medical University Hospital /ID# 214062, Taichung
Univ Hosp Cleveland /ID# 201567, Cleveland
Duplicate_Henry Ford Hospital /ID# 226852, Detroit
Highlands Oncology Group, PA /ID# 201568, Springdale
Mary Crowley Cancer Research /ID# 214168, Dallas
MD Anderson Cancer Center /ID# 201558, Houston
NEXT Oncology /ID# 204893, San Antonio
Univ of Colorado Cancer Center /ID# 208365, Aurora
Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 204267, West Hollywood
Rambam Health Care Campus /ID# 230813, Haifa
The Chaim Sheba Medical Center /ID# 230812, Ramat Gan
UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105, Orange
Yale University, Yale Cancer Center /ID# 201542, New Haven
Northwestern University Feinberg School of Medicine /ID# 201563, Chicago
Dana-Farber Cancer Institute /ID# 201564, Boston
Northwell Health - Marcus Ave /ID# 204376, New Hyde Park
University of Oklahoma, Stephenson Cancer Center /ID# 206820, Oklahoma City
Lifespan Cancer Institute at Rhode Island Hospital /ID# 204256, Providence
Vanderbilt Ingram Cancer Center /ID# 201575, Nashville
Cross Cancer Institute /ID# 213838, Edmonton
University Health Network_Princess Margaret Cancer Centre /ID# 204539, Toronto
National Cancer Center Hospital East /ID# 215130, Kashiwa-shi
National Cancer Center Hospital /ID# 215003, Chuo-ku
Maastricht Universitair Medisch Centrum /ID# 225220, Maastricht
Antoni van Leeuwenhoek /ID# 222260, Amsterdam
Erasmus Medisch Centrum /ID# 222341, Rotterdam
Universitair Medisch Centrum Utrecht /ID# 222357, Utrecht
Pan American Center for Oncology Trials, LLC /ID# 232128, Rio Piedras
Yonsei University Health System Severance Hospital /ID# 240648, Seoul
Lead Sponsor
AbbVie
INDUSTRY